Physician profile
Sara E Mueller
NPI 1811348105
$2,971.69
in general payments reported to CMS, 2019-2025
27 companies · $845 in 2025
The $845 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $613 · 2023: $680 · 2024: $834 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $794.14 | 2022-2025 | |
| Novo Nordisk INC | $557.88 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $305.64 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $191.70 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $141.91 | 2022-2025 | Caplyta |
| Pfizer INC. | $129.04 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.73 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $94.85 | 2022-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Exact Sciences Corporation | $89.43 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $69.56 | 2022-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $65.43 | 2024-2025 | Veozah |
| Alnylam Pharmaceuticals INC. | $58.31 | 2023-2024 | Onpattro |
| Otsuka America Pharmaceutical, INC. | $54.69 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $46.13 | 2024-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $29.31 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $28.35 | 2022 | |
| Corium, LLC | $27.16 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.39 | 2022 | |
| Biogen, INC. | $20.49 | 2025 | Zurzuvae |
| Abbott Laboratories | $19.13 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $18.30 | 2025 | Rexulti |
| Covis Pharma Gmbh | $16.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.79 | 2025 | Voquezna |
| Alexion Pharmaceuticals, INC. | $15.44 | 2022 | |
| Axonics, INC. | $14.94 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.37 | 2022 | |
| Boston Scientific Corporation | $13.53 | 2025 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.